Message #30 From:
NewsBot Date: December 19, 2006 09:19:00 AM
CHHH News China Health Holding to be Added to China Small-Cap Index
LAS VEGAS--(BUSINESS WIRE)--China Health Holding (OTCBB: CHHH),
a developer, manufacturer, marketer and distributor of pharmaceutical
products and dietary supplements in China and worldwide, announced today
that it will be added to the Ludlow China Small-Cap Index in Jan 2007, a
diversified stock index of Chinese stocks traded in the U.S. financial
markets owned and operated by the New York-based investment banking firm Ludlow
China Fund, Inc.
Julianna Lu, The Company’s Founder and CEO
said, "Ludlow's decision to add CHHH to its index of small-cap Chinese
stocks is yet another indication of CHHH's increasing exposure amongst
the U.S. investment community. As in all indexing, this designation will
automatically introduce the CHHH investment story to new investors who
are interested in 'buying the market' by duplicating the basket that the
index defines -- in this case small-cap China- based stocks. Also,
inclusion on a China Small-Cap Index implicitly recognizes that CHHH now
has the liquidity, market capitalization and strong financial track
record to be an appropriate investment for institutions with indexed
portfolios.”
About China Health Holding
China Health Holding, Inc. is a developer, manufacturer and marketer of
natural medicinal products and pharmaceutical drugs in China and
worldwide, with extensive expertise in the field of traditional Chinese
medicine and the Chinese pharmaceutical industry. Its immediate goal is
the profitable penetration of the growing global and China
pharmaceutical industry and market through acquisitions of major
pharmaceutical companies in the People's Republic of China and
worldwide. Its long-term plans include the development of a
pharmaceutical drug pipeline and technology based on its knowledge of
traditional Chinese medicine and the pharmaceutical industry in the
People's Republic of China.
Acquisition is the Company’s comprehensive
growth strategy. The Company has announced a few pending or completed
acquisitions of China-based pharmaceutical firms in recent months. The
Company has executed binding acquisition letters of intent to acquire
51% or more of Beijing Boran Pharmaceutical Co. Ltd., Xi’An
ChunHui Pharmaceuticals, Co. Ltd., Shaanxi Wanan Pharmaceuticals Co.
Ltd.; and Henan Tiankang Pharmaceuticals Co. Ltd and all letters give
China Health legal first refusal and exclusive rights. It has executed
"Acquisition Definitive Agreements" for acquiring 100% of Shaanxi
MeiChen Pharmaceuticals, Ltd. and 60% of Henan Furen Huaiqingtang
Pharmaceuticals Co. Ltd. Also, it has signed a letter of intent with
WangJing Hospital and the WangJing Hospital of China Academy of Chinese
Medical Sciences, in the People's Republic of China, to develop the
China International University of Traditional Chinese Medicine and the
University Hospital for Traditional Chinese Medical Sciences. Through
these acquisition transactions, the Company is in the process of
building a powerful network of established China-SFDA-certified
pharmaceutical drug manufacturing facilities along with extensive
hospital and drugstore distribution channels in China. The Company will
also have an enhanced pipeline of hundreds of China-SFDA certified
pharmaceutical drugs."
In the next 12 to 24 months, China Health plans to complete further
acquisitions and transactions with major pharmaceutical companies in the
People's Republic of China, bringing its total assets to approximately
US$100 million. At the end of this process, it projects annual gross
revenue of approximately US$100 million, with annual net income of
approximately US$10 million to US$15 million.
The company has two wholly-owned subsidiaries. One is China Health World
Pharmaceutical Corporation, which will develop, manufacture and
commercialize natural medications for diseases and conditions related to
diabetes, cardiovascular disease and neurological disorders. The other
subsidiary, China Health World Trade Corporation, will be developing
China Health's retail/franchise infrastructure along with worldwide
branding, multimedia marketing and multi-channel distribution to global
customers and markets.
China Health controls or owns exclusive worldwide ownership or rights
for a total of 134 proprietary natural herbal medicinal
products/formulas in two natural herbal medicinal product lines: King of
Herbs and Taoist Medicinal. Please feel free to visit www.chinahealthholding.com
for the Company's profile.
Safe Harbor Statement: To the extent that statements in the press
release are not strictly historical, including statements as to revenue
projections, business strategy, outlook, objectives, future milestones,
plans, intentions, goals, future financial conditions, future
collaboration agreements, the success of the Company's development,
events conditioned on stockholder or other approval, or otherwise as to
future events, such statements are forward looking, all forward-looking
statements, whether written or oral, and whether made by or on behalf of
the Company, are expressly qualified by the cautionary statements and
any other cautionary statements, which may accompany the forward-looking
statements, and are made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. The forward-looking
statements contained in this release are subject to certain risks and
uncertainties that could cause actual results to differ materially from
the statements made. Other important factors that could cause actual
results to differ materially include the following: business conditions
and the amount of growth in the Company's industry and general economy;
competitive factors; ability to attract and retain personnel; the price
of the Company's stock; and the risk factors set forth from time to time
in the Company's SEC reports, including but not limited to its annual
report on Form 10-KSB; its quarterly reports on Forms 10-QSB; and any
reports on Form 8-K. In addition, the company disclaims any obligation
to update or correct any forward-looking statements in all of the
Company's press releases to reflect events or circumstances after the
date hereof.
